# Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

> **NCT02446691** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 128 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** MenACWY

## Key facts

- **NCT ID:** NCT02446691
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446691, "Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02446691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*